Pacific Biosciences Of California (PACB) Assets Average (2010 - 2026)

Pacific Biosciences Of California's Assets Average history runs 17 years deep, the most recent figure standing at $783.2 million for Q1 2026.

• On a quarterly basis, Assets Average fell 26.15% year-over-year to $783.2 million in Q1 2026; TTM through Mar 2026 was $783.2 million, a 26.15% decrease from a year earlier, with the FY2025 full-year figure at $1.0 billion, down 32.0% from the prior year.
• Assets Average eased to $783.2 million in Q1 2026 per PACB's latest filing, from $793.6 million in the prior quarter.
• Across five years, Assets Average topped out at $2.0 billion in Q1 2022 and bottomed at $783.2 million in Q1 2026.
• The 5-year median for Assets Average is $1.7 billion (2024), against an average of $1.5 billion.
• Across the five-year window, Assets Average surged 195.85% in 2022 and sank 46.96% in 2025, its largest moves.
• Year by year, Assets Average stood at $1.8 billion in 2022, then increased by 1.63% to $1.8 billion in 2023, then retreated by 25.62% to $1.4 billion in 2024, then sank by 41.44% to $793.6 million in 2025, then declined by 1.31% to $783.2 million in 2026.
• Per Business Quant, the three latest PACB Assets Average figures stand at $783.2 million (Q1 2026), $793.6 million (Q4 2025), and $814.3 million (Q3 2025).